...
首页> 外文期刊>Military Medicine: Official Journal of AMSUS, The Society of the Federal Health Agencies >Development of chemopreventive strategies for radiation-induced cancer: targeting radiation-induced genetic alterations.
【24h】

Development of chemopreventive strategies for radiation-induced cancer: targeting radiation-induced genetic alterations.

机译:放射致癌化学预防策略的发展:以放射致遗传改变为目标。

获取原文
获取原文并翻译 | 示例

摘要

Carcinogenesis is a multistage process involving dysregulation of signal transduction and cell cycle pathways. This dysregulation results in specific molecular and genetic alterations, including gene amplification, mutations, and chromosomal rearrangements. These aberrations can be measured to provide a novel means to assess carcinogenic risk or as targets for chemointervention. Recent human and in vivo studies have demonstrated that genetic alterations, such as oncogenes and oncoproteins, were observed in preneoplastic tissues or serum following exposure to chemical carcinogens or low-level radiation (LLR). Identification of preneoplastic changes following radiation exposure may provide information that will allow development of LLR chemopreventive strategies. Radiation carcinogenesis studies in vivo with a lung tumor model showed that a low-dose cobalt-60 radiation exposure induced persistent time-dependent genetic alterations, such as elevated ras expression. This radiation exposure also resulted inlung tumor formation in 26% of the irradiated animals at 232 days after irradiation. A significant and progressive increase in ras oncogene expression was measured using Northern blot analysis in 80% of the irradiated animals over the duration of the experiment. Pharmacological intervention strategies are being tested using buthionine-[S,R]-sulfoximine (BSO). BSO has been previously shown to down-regulate ras expression. Administration of BSO prevented radiation-induced changes in ras mRNA levels in this lung tumor model. Further studies are being conducted with an LLR-induced leukemia model in which detection of circulating levels of oncoproteins will be more feasible. Based on these preliminary results and on its clinical efficacy and low clinical toxicity, BSO warrants further study as an LLR chemopreventive agent. Furthermore, this strategy to target LLR-induced preneoplastic alterations may be an effective means of developing modulators of LLR-induced cancers.
机译:癌变是一个多阶段过程,涉及信号转导和细胞周期途径的失调。这种失调导致特定的分子和遗传改变,包括基因扩增,突变和染色体重排。可以测量这些像差,以提供一种新颖的方法来评估致癌风险或作为化学干预的目标。最近的人体和体内研究表明,暴露于化学致癌物或低水平辐射(LLR)后,在肿瘤形成前的组织或血清中观察到遗传改变,例如癌基因和癌蛋白。识别辐射暴露后的肿瘤前变化可能会提供信息,从而有助于制定LLR化学预防策略。用肺肿瘤模型进行的体内放射致癌研究表明,低剂量的60号钴暴露会引起持续的时间依赖性遗传改变,例如ras表达升高。这种辐射暴露还导致在辐射后232天,在26%的受辐射动物中形成了肺部肿瘤。在整个实验过程中,使用Northern印迹分析在80%的受辐照动物中测量了ras癌基因表达的显着和逐步增加。正在使用丁硫氨酸-[S,R]-亚磺酰亚胺(BSO)测试药理干预策略。以前已证明BSO下调ras表达。在该肺肿瘤模型中,BSO的使用可防止辐射诱导的ras mRNA水平变化。正在用LLR诱导的白血病模型进行进一步的研究,在该模型中检测癌蛋白的循环水平将更为可行。基于这些初步结果及其临床疗效和低临床毒性,BSO作为LLR化学预防剂值得进一步研究。此外,这种针对LLR诱导的肿瘤前改变的策略可能是开发LLR诱导的癌症调节剂的有效手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号